NEW YORK--(BUSINESS WIRE)--Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Bryan Spielman has been named executive vice president of strategy and corporate development, reporting to CEO Tarek Sherif and President Glen de Vries. Bryan will oversee strategic planning and corporate development activities with a focus on strengthening Medidata through strategic partnerships and corporate initiatives that will continue to drive competitive advantage for its clinical research customers.
Bryan brings more than 20 years of experience to Medidata. He joins the company after serving as an advisor to leading global technology companies, most recently as partner and managing director at Centerview Partners. At Centerview, his responsibilities included transaction origination and evaluation, corporate strategy, strategic positioning, as well as advising on financings, capital structure and investor communications.
“Bryan’s extensive experience advising technology companies will be a key asset for us as we continue to strengthen relationships with a range of technology and life sciences companies and form new partnerships with influential players in our market,” said Tarek Sherif, CEO, Medidata Solutions. “As we’re continually evaluating additional opportunities for expansion, Bryan will play a critical role in driving our corporate strategy and future growth.”
Previously, Bryan held leadership roles in the technology investment banking groups at UBS Investment Bank and Bear Stearns, where he worked extensively with leading global technology companies and private-equity sponsors on a broad range of advisory and financing transactions.
Bryan holds a BA from the University of Pennsylvania and an MBA from New York University’s Stern School of Business.
About Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.